Skip to main content

Table 3 Factors associated with patients’ progression-free survival

From: Impact of hemodynamic instability during cytoreductive surgery on survival in high-grade serous ovarian carcinoma

Variables Univariate analysis Multivariate analysis
HR (95% CI) P aHR (95% CI) P aHR (95% CI) P aHR (95% CI) P aHR (95% CI) P
FIGO stage
 III-IV (n = 290) vs. I-II (n = 48) 4.973 (2.631–9.399) < 0.001 2.729 (1.397–5.331) 0.003 2.915 (1.494–5.687) 0.002 2.933 (1.504–5.720) 0.002 2.913 (1.494–5.677) 0.002
Neoadjuvant chemotherapy
 Yes (n = 113) vs. No (n = 225) 2.160 (1.639–2.845) < 0.001 2.107 (1.572–2.823) < 0.001 2.003 (1.497–2.680) < 0.001 1.973 (1.471–2.646) < 0.001 1.994 (1.489–2.671) < 0.001
Operative time, h
  ≥5.0 (n = 161) vs. <5.0 (n = 177) 1.477 (1.125–1.938) 0.005 1.331 (1.003–1.767) 0.048 1.325 (0.998–1.759) 0.052 1.358 (1.023–1.802) 0.034 1.392 (1.048–1.849) 0.022
Residual tumor after surgery
 Residual (n = 85) vs. R0 (n = 253) 2.555 (1.897–3.442) < 0.001 2.333 (1.719–3.168) < 0.001 2.323 (1.713–3.150) < 0.001 2.267 (1.671–3.076) < 0.001 2.279 (1.681–3.091) < 0.001
MAP under 65 mmHg, min
 Continuous (n = 338) 1.002 (0.999–1.005) 0.289         
  ≥30.0 (n = 107) vs. <30.0 (n = 231) 1.423 (1.073–1.887) 0.014 1.376 (1.035–1.830) 0.028       
MDPE (%)
 Continuous (n = 338) 0.993 (0.981–1.005) 0.244         
  <−4.0 (n = 183) vs. ≥−4.0 (n = 155) 1.349 (1.025–1.775) 0.032    1.351 (1.024–1.783) 0.033     
Wobble (%)
 Continuous (n = 338) 1.096 (1.032–1.165) 0.003      1.082 (1.018–1.150) 0.012   
  ≥7.5 (n = 159) vs. <7.5 (n = 179) 1.449 (1.106–1.900) 0.007        1.445 (1.100–1.899) 0.008
  1. Abbreviations: aHR Adjusted hazard ratio, BMI Body mass index, CI Confidence interval, FIGO International Federation of Gynecology and Obstetrics, HR Hazard ratio, MAP Mean arterial blood pressure, MDPE Median performance error, R0 Complete cytoreduction